-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stem Cell Therapy For Systemic Lupus Erythematosus in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Stem Cell Therapy For Systemic Lupus Erythematosus in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stem Cell Therapy For Systemic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Sicca Syndrome (Sjogren) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adipose Tissue Derived Mesenchymal Stromal/Stem...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stem Cell Therapy For Alzheimer’s Disease, Osteoarthritis And Rheumatoid Arthritis in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Stem Cell Therapy For Alzheimer's Disease, Osteoarthritis And Rheumatoid Arthritis in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stem Cell Therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adipose Tissue Derived Mesenchymal Stromal/Stem Cells in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adipose Tissue Derived Mesenchymal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For Multiple Myeloma And Stem Cell Transplantation in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For Multiple Myeloma And Stem Cell Transplantation in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy...
-
Product Insights
NewHematopoietic Stem Cell Transplantation – Drugs In Development, 2024
Empower your strategies with our Hematopoietic Stem Cell Transplantation – Drugs In Development, 2024 report and make more profitable business decisions. Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from...
-
Product Insights
NewLimbal Stem Cell Deficiency (LSCD) – Drugs In Development, 2024
Empower your strategies with our Limbal Stem Cell Deficiency (LSCD) – Drugs In Development, 2024 report and make more profitable business decisions. Limbal Stem Cell Deficiency (LSCD) is characterized by a loss or deficiency of the stem cells in the limbus that are important for the regeneration of corneal epithelium and to the barrier function of the limbus. Due the loss of stem cells, the corneal epithelium is unable to repair and renew itself, resulting in in epithelial breakdown and persistent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Exagamglogene Autotemcel in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Exagamglogene Autotemcel in Sickle Cell Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Exagamglogene Autotemcel in Sickle Cell Disease Drug Details: Exagamglogene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – It-hMSC in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - It-hMSC in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. It-hMSC in Congestive Heart Failure (Heart Failure) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug...